Enliven Therapeutics (ELVN) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Parabilis Medicines is the larger company by market cap ($3.39 billion vs $3.00 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | PBLS |
|---|---|---|
| Share price | $40.98 | $27.48 |
| Market cap | $3.00B | $3.39B |
| 1-day change | +0.86% | -2.17% |
| YTD return | +166.10% | — |
| 1-year return | +92.48% | — |
| 5-year return | +179.92% | — |
| EPS (TTM) | $-1.67 | $-9.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-103.69M | — |
| 52-week high | $62.32 | $42.49 |
| 52-week low | $14.79 | $24.51 |
| Distance from 52-week high | -34.24% | -35.33% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +79.77% | +51.93% |
| Average volume | 1.14M | 697.10K |
| Shares outstanding | 73.27M | 121.95M |
| Employees | 67 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
ELVN vs PBLS FAQ
Which is bigger, Enliven Therapeutics or Parabilis Medicines?
Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.39B compared with $3.00B for Enliven Therapeutics (ELVN).
Are Enliven Therapeutics and Parabilis Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.